☆ 4.7 Meeting Abstract

ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor plus palbociclib (AI plus P) for metastatic breast cancer (MBC) in the PADA-1 trial

ANNALS OF ONCOLOGY (2020)

Journal

ANNALS OF ONCOLOGY

Volume 31, Issue -, Pages S364-S364

Publisher

ELSEVIER

DOI: 10.1016/j.annonc.2020.08.406

Keywords

Funding

Pfizer

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor plus palbociclib (AI plus P) for metastatic breast cancer (MBC) in the PADA-1 trial

Journal

ANNALS OF ONCOLOGY

Publisher

ELSEVIER

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor plus palbociclib (AI plus P) for metastatic breast cancer (MBC) in the PADA-1 trial

Journal

ANNALS OF ONCOLOGY

Publisher

ELSEVIER

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper